O
SGEN

OrbiMed’s Seagen Inc. Common Stock SGEN Stock Holding History

OrbiMed’s Portfolio SGEN Stock Details SGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-42,600
Closed -$9.04M – 140
2023
Q3 		$9.04M Buy
+42,600
New +$8.51M 0.19% 86
2023
Q1 		– Sell
-913,812
Closed -$117M – 138
2022
Q4 		$117M Buy
913,812
+151,212
+20% +$19.5M 2.25% 13
2022
Q3 		$104K Buy
762,600
+75,100
+11% +$12.2M 1.94% 15
2022
Q2 		$122K Buy
687,500
+19,800
+3% +$2.85M 2.2% 12
2022
Q1 		$96.2M Buy
667,700
+12,100
+2% +$1.64M 1.56% 21
2021
Q4 		$101M Buy
655,600
+387,600
+145% +$64.9M 1.3% 26
2021
Q3 		$45.5M Buy
+268,000
New +$41.7M 0.5% 56

Other funds holding SGEN

SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return

OrbiMed's SGEN Position: Q4 2023 in Review

OrbiMed sold out of Seagen Inc. Common Stock (SGEN) in Q4 2023, closing a stake of 42,600 shares — an estimated $9.04M sold.

OrbiMed first reported a position in SGEN in Q3 2021 and held it in 7 quarters. The position peaked at $117M in Q4 2022. 6 funds tracked by Wall St. Rank hold SGEN as of Q4 2023.

  • OrbiMed reported no remaining Seagen Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • OrbiMed sold 42,600 Seagen Inc. Common Stock shares in Q4 2023, an estimated $9.04M.
  • OrbiMed first reported a position in Seagen Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • OrbiMed's Seagen Inc. Common Stock position peaked at $117M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Seagen Inc. Common Stock as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.